1. Home
  2. KRMD vs IPHA Comparison

KRMD vs IPHA Comparison

Compare KRMD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

HOLD

Current Price

$3.16

Market Cap

192.5M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.87

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRMD
IPHA
Founded
1980
1999
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.5M
165.3M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
KRMD
IPHA
Price
$3.16
$1.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$6.50
$5.75
AVG Volume (30 Days)
221.0K
52.7K
Earning Date
05-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
N/A
EPS
N/A
N/A
Revenue
$41,127,366.00
N/A
Revenue This Year
$20.32
$180.36
Revenue Next Year
$17.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.23
N/A
52 Week Low
$3.12
$1.18
52 Week High
$6.61
$2.71

Technical Indicators

Market Signals
Indicator
KRMD
IPHA
Relative Strength Index (RSI) 29.99 41.28
Support Level N/A $1.67
Resistance Level $3.43 $1.95
Average True Range (ATR) 0.10 0.08
MACD 0.02 -0.05
Stochastic Oscillator 11.11 0.00

Price Performance

Historical Comparison
KRMD
IPHA

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: